FDA grants orphan-drug status to Erytech's leukemia drug

01/27/2010 | American City Business Journals

Graspa, Erytech Pharma's drug candidate for acute lymphoblastic leukemia, received orphan-drug designation from the FDA. The drug is a novel L-asparaginase formulation packed in red blood cells to make it safer. Erytech is considering starting clinical trials of the drug in the U.S., CEO Yann Godfrin said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC